|
市場調査レポート
商品コード
1671846
肺動脈性肺高血圧症治療薬市場：薬剤クラス別、投与経路別、タイプ別、性別、流通チャネル別、地域別Pulmonary Arterial Hypertension Drug Market, By Drug Class, By Route of Administration, By Type, By Gender, By Distribution Channel, By Geography |
||||||
カスタマイズ可能
|
|||||||
| 肺動脈性肺高血圧症治療薬市場：薬剤クラス別、投与経路別、タイプ別、性別、流通チャネル別、地域別 |
|
出版日: 2025年02月26日
発行: Coherent Market Insights
ページ情報: 英文 163 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
肺動脈性肺高血圧症治療薬の世界市場は、2025年には85億8,000万米ドルと推定され、2032年には128億1,000万米ドルに達すると予測され、2025年から2032年までの年間平均成長率（CAGR）は5.9%で成長すると予測されています。
| レポート範囲 | レポート詳細 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年の市場規模 | 85億8,000万米ドル |
| 実績データ | 2020年から2024年まで | 予測期間 | 2025年から2032年 |
| 予測期間：2025年～2032年 CAGR： | 5.90% | 2032年の価値予測 | 128億1,000万米ドル |
世界の肺動脈性肺高血圧症治療薬市場は、過去数年にわたって着実な成長を遂げています。肺動脈性肺高血圧症は、心臓と肺をつなぐ動脈の血圧が異常に高いことを特徴とする疾患です。過剰な圧力は、酸素を得るために肺を通して血液を送り出す心臓の働きを悪くします。治療が遅れると、症状が悪化し、心不全に至ることもあります。危険因子の増加による肺動脈性肺高血圧症の有病率の増加、新しく効果的な治療薬の承認、診断の改善といった要因が、特定の薬剤に対する需要を世界的に牽引しています。しかし、高い治療費と薬剤の長期使用に伴う副作用は、依然として大きな課題となっています。
市場力学：
世界の肺動脈性肺高血圧症治療薬市場は、高齢化、遺伝的素因、その他の病状などの危険因子の増加による肺動脈性肺高血圧症の有病率の増加などの要因によって牽引されています。国立医学図書館の推計によると、2024年11月には北米と欧州で10万人以上が肺動脈性肺高血圧症に罹患しています。さらに、プロスタサイクリン類似物質、エンドセリン受容体拮抗薬、ホスホジエステラーゼ-5阻害薬など、有効性と利便性を向上させる新薬の承認も市場の成長を後押ししています。しかし、ブランド薬の高価格が依然として主要な阻害要因となっています。肺動脈性肺高血圧症の治療には生涯にわたる投薬が必要であり、毎年数千ドルの費用がかかります。このため、薬へのアクセスが制限されています。とはいえ、低コストのジェネリック医薬品の出現は、市場プレーヤーに新たな機会をもたらすと期待されています。
本調査の主な特徴
本レポートでは、世界の肺動脈性肺高血圧症治療薬市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模および複合年間成長率（CAGR%）を掲載しています。
また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
世界の肺動脈性肺高血圧症治療薬市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。
本調査の対象となる主要企業には、United Therapeutics Corporation、Actelion Pharmaceuticals（a Janssen Pharmaceutical Company）、Bayer AG、Gilead Sciences, Inc.、Merck &Co, Inc.、GlaxoSmithKline plc、Pfizer Inc.、Novartis International AG、Teva Pharmaceutical Industries Ltd.、Amgen Inc.、Bristol-Myers Squibb Company、Arena Pharmaceuticals、Sun Pharmaceutical Industries Ltd.、Sandoz Inc.、Lupin Pharmaceuticals, Inc.などがあります。
本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
世界の肺動脈性肺高血圧症治療薬市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
利害関係者は、世界の肺動脈性肺高血圧症治療薬市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。
目次
第1章 調査の目的と前提条件
- 調査目的
- 前提条件
- 略語
第2章 市場の展望
- レポートの説明
- 市場の定義と範囲
- エグゼクティブサマリー
第3章 市場力学、規制、動向分析
- 市場力学
- ドライバ
- 抑制要因
- 機会
- 影響分析
- 主な発展
- 規制シナリオ
- 製品の発売/承認
- PEST分析
- PORTERの分析
- 合併と買収のシナリオ
- 業界動向
第4章 世界の肺動脈性肺高血圧症治療薬市場、薬剤クラス別、2020年～2032年
- プロスタサイクリンおよびプロスタサイクリン類似体
- エンドセリン受容体拮抗薬（ERA）
- ホスホジエステラーゼ5阻害剤（PDE-5阻害剤）
- 可溶性グアニル酸シクラーゼ（sGC）刺激剤
- その他の薬物クラス
第5章 世界の肺動脈性肺高血圧症治療薬市場、投与経路別、2020年～2032年
- 経口
- 静脈内
- 皮下
- 吸入
第6章 世界の肺動脈性肺高血圧症治療薬市場、タイプ別、2020年～2032年
- ブランド医薬品
- ジェネリック医薬品
第7章 世界の肺動脈性肺高血圧症治療薬市場、性別、2020年～2032年
- 男性
- 女性
第8章 世界の肺動脈性肺高血圧症治療薬市場、流通チャネル別、2020年～2032年
- 病院薬局
- 小売薬局
- オンライン薬局
第9章 世界の肺動脈性肺高血圧症治療薬市場、地域別、2020年～2032年
- 北米
- ラテンアメリカ
- 欧州
- アジア太平洋
- 中東
- アフリカ
第10章 競合情勢
- United Therapeutics Corporation
- Actelion Pharmaceuticals
- Bayer AG
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Arena Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- Sandoz Inc.
- Lupin Pharmaceuticals, Inc.
第11章 アナリストの推奨事項
- 運命の輪
- アナリストの見解
- 一貫した機会マップ
第12章 参考文献と調査手法
- 参考文献
- 調査手法
- 出版社について
Global Pulmonary Arterial Hypertension Drug Market is estimated to be valued at US$ 8.58 Bn in 2025 and is expected to reach US$ 12.81 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | US$ 8.58 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.90% | 2032 Value Projection: | US$ 12.81 Bn |
The global pulmonary arterial hypertension drug market has been witnessing steady growth over the past few years. Pulmonary arterial hypertension is a condition characterized by abnormally high blood pressure in the arteries connecting the heart and lungs. The excessive pressure makes the heart work harder to pump blood through the lungs to obtain oxygen. If not treated on time, the condition can lead to worsening symptoms and even heart failure. Factors such as the growing prevalence of pulmonary arterial hypertension due to increasing risk factors, approval of new and effective treatment drugs, and improved diagnosis are driving the demand for specific drugs globally. However, high treatment costs and side effects associated with long term use of drugs continue to remain major challenges.
Market Dynamics:
The global pulmonary arterial hypertension drug market is driven by factors such as the increasing prevalence of pulmonary arterial hypertension due to growing risk factors like older age, genetic predisposition, and other medical conditions. In November 2024, according to National Library of Medicine estimates, more than 100,000 people in North America and Europe suffer from pulmonary arterial hypertension. Furthermore, approval of new drugs such as prostacyclin analogs, Endothelin receptor antagonists, Phosphodiesterase-5 inhibitors, and others which offer improved efficacy and convenience is also fueling market growth. However, the high cost of branded drugs remains a key restraint. Treatment of pulmonary arterial hypertension requires life-long medication which costs thousands of dollars every year. This limits accessibility to medication. Nevertheless, emergence of low-cost generic drugs is expected to create new opportunities for market players.
Key Features of the Study:
This report provides in-depth analysis of the global pulmonary arterial hypertension drug market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global pulmonary arterial hypertension drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include United Therapeutics Corporation, Actelion Pharmaceuticals (a Janssen Pharmaceutical Company), Bayer AG, Gilead Sciences, Inc., Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, Teva Pharmaceutical Industries Ltd., Amgen Inc., Bristol-Myers Squibb Company, Arena Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Sandoz Inc., and Lupin Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global pulmonary arterial hypertension drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pulmonary arterial hypertension drug market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Prostacyclin and Prostacyclin Analogs
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 Inhibitors (PDE-5 Inhibitors)
- Soluble Guanylate Cyclase (sGC) Stimulators
- Other Drug Classes
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Intravenous
- Subcutaneous
- Inhalation
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded Drugs
- Generic Drugs
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- United Therapeutics Corporation
- Actelion Pharmaceuticals
- Bayer AG
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Arena Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- Sandoz Inc.
- Lupin Pharmaceuticals, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Pulmonary Arterial Hypertension Drug Market, By Drug Class
- Global Pulmonary Arterial Hypertension Drug Market, By Route of Administration
- Global Pulmonary Arterial Hypertension Drug Market, By Type
- Global Pulmonary Arterial Hypertension Drug Market, By Gender
- Global Pulmonary Arterial Hypertension Drug Market, By Distribution Channel
- Global Pulmonary Arterial Hypertension Drug Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Pulmonary Arterial Hypertension Drug Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Prostacyclin and Prostacyclin Analogs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Endothelin Receptor Antagonists (ERAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Phosphodiesterase-5 Inhibitors (PDE-5 Inhibitors)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Soluble Guanylate Cyclase (sGC) Stimulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Drug Classes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Pulmonary Arterial Hypertension Drug Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Inhalation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Pulmonary Arterial Hypertension Drug Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Branded Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Pulmonary Arterial Hypertension Drug Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Pulmonary Arterial Hypertension Drug Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Pulmonary Arterial Hypertension Drug Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- United Therapeutics Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Actelion Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Bristol-Myers Squibb Company
- Arena Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- Sandoz Inc.
- Lupin Pharmaceuticals, Inc.
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
